Participant flow

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma · Source last updated 2026-04-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II. \> \> \> \> \> \> Laboratory Biomarker Analysis: Correlative studies \> \> \> \> \> \> Pembrolizumab: Given IV \> \> \> \> \> \> Pharmacological Study: Correlative studies

   id

   FG000

   title

   Phase 2 Group I (Pembrolizumab)

2. description

   Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity. \> \> \> \> \> \> Anetumab Ravtansine: Given IV \> \> \> \> \> \> Laboratory Biomarker Analysis: Correlative studies \> \> \> \> \> \> Pembrolizumab: Given IV \> \> \> \> \> \> Pharmacological Study: Correlative studies

   id

   FG001

   title

   Phase 2 Group II (Anetumab Ravtansine, Pembrolizumab)

3. description

   Anetumab Ravtansine Dose 6.5 mg/kg

   id

   FG002

   title

   Phase 1 Cohort Dose Level 1

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         18

      2. group Id

         FG001

         num Subjects

         18

      3. group Id

         FG002

         num Subjects

         13

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         18

      2. group Id

         FG001

         num Subjects

         17

      3. group Id

         FG002

         num Subjects

         13

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice